Optimizing the Plasmid Foundation for AAV Manufacturing
The efficiency of AAV vector production is heavily influenced by the quality of its foundational components, particularly the three plasmids used in standard triple-transfection protocols: the ITR-containing plasmid with the gene of interest, the Rep/Cap plasmid, and the helper plasmid. Any instability or suboptimal design in these starting materials can propagate through the manufacturing process, resulting in diminished yields and inconsistent product quality.
Our approach centers on rigorous design and qualification of every plasmid. This includes a multi-point quality control process to ensure the structural integrity of the ITRs, which are fundamental for replication and packaging. We also provide strategic guidance on the selection of promoters, enhancers, and polyadenylation signals to construct a gene cassette that drives robust and specific expression in the target tissue.
This optimization must also account for the intended AAV serotype and its target application. Different serotypes exhibit distinct tropisms and transduction efficiencies in specific cell types, such as the high efficiency observed for serotypes 1, 2, 7, 8, and 9 in primary neuronal cultures (PMID: 18054899). The plasmid design must be harmonized with the serotype being produced to achieve the desired biological outcome.
Our scientific continuity ensures that programs benefit from decades of institutional knowledge. This expertise provides a stable foundation for long-term development, as exemplified by a collaborator whose AAV-vector based gene therapy program transitioned without interruption when key personnel from the UPenn Vector Core joined our organization. This deep experience, combined with our >100,000 sq ft facility, enables us to guide programs toward an 18-24 month IND timeline.
